The endogenous lipid N-arachidonoyl glycine is hypotensive and nitric oxide-cGMP-dependent vasorelaxant

Yousuf M. Al Suleimani, Ahmed S. Al Mahruqi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

N-arachidonoyl glycine (NAGLY), is the endogenous lipid that activates the G protein-couple receptor 18 (GPR18) with vasodilatory activity in resistance arteries. This study investigates its hemodynamic effects and mechanisms of vasorelaxation. Hemodynamic effects of NAGLY in rats were assessed using a Biopac system and its vascular responses were assessed using a wire myograph. NAGLY (1 mg/kg) decreased blood pressure by 69.4±5.5% and reduced renal blood flow by 88±12% and the effects were not sensitive to inhibition by O-1918 (3 mg/kg). In resistant vessels, NAGLY (1–30 µM) induced concentration- and endothelium-dependent vasorelaxation and the effect was inhibited by the nitric oxide synthase inhibitor, L-NAME (300 µM), a cGMP synthase inhibitor, ODQ (10 µM), the antagonists of “endothelial anandamide” receptor, rimonabant (3 µM) and O-1918 (10 µM) and the inhibitor of Na+/Ca2+ exchanger (NCX), KB-R7943 (10 µM). On the other hand, NAGLY-induced vasorelaxation was not affected by CID 16020046 (GPR55 antagonist), AM 251 (cannabinoid CB1 receptor antagonist), AM 630 (cannabinoid CB2 receptor antagonist), capsazepine (TRPV1 antagonist), indomethacin (cyclooxygenase inhibitor), TRAM34 (IKCa channel blocker), iberiotoxin (BKCa channel blocker) and GW9662 (PPARɤ antagonist). At low concentrations of carbachol, NAGLY potentiated carbachol-induced vasorelaxation. NAGLY is an endothelium-dependent vasodilator and hypotensive lipid. The vasorelaxation is predominantly via activation of nitric oxide-cGMP pathway and NCX and probably mediated by the "endothelial anandamide” receptor, while the hypotensive effect of NAGLY appears not to involve the anandamide receptor. NAGLY also potentiates carbachol-induced vasorelaxation, the mechanism of which might involve stimulation of NO release.

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalEuropean Journal of Pharmacology
Volume794
DOIs
Publication statusPublished - Jan 5 2017

Fingerprint

Vasodilator Agents
Nitric Oxide
Lipids
Vasodilation
Carbachol
Cannabinoid Receptor Antagonists
rimonabant
Hemodynamics
N-arachidonylglycine
Endothelium-Dependent Relaxing Factors
Peroxisome Proliferator-Activated Receptors
Cyclooxygenase Inhibitors
Renal Circulation
NG-Nitroarginine Methyl Ester
GTP-Binding Proteins
Nitric Oxide Synthase
Indomethacin
Endothelium
Blood Vessels
Arteries

Keywords

  • Hypotensive
  • N-arachidonoyl glycine
  • Na/Ca exchanger
  • Nitric oxide
  • Vasorelaxation

ASJC Scopus subject areas

  • Pharmacology

Cite this

The endogenous lipid N-arachidonoyl glycine is hypotensive and nitric oxide-cGMP-dependent vasorelaxant. / Al Suleimani, Yousuf M.; Al Mahruqi, Ahmed S.

In: European Journal of Pharmacology, Vol. 794, 05.01.2017, p. 209-215.

Research output: Contribution to journalArticle

@article{f8645fc322bb44c189f59c6f8cc939e8,
title = "The endogenous lipid N-arachidonoyl glycine is hypotensive and nitric oxide-cGMP-dependent vasorelaxant",
abstract = "N-arachidonoyl glycine (NAGLY), is the endogenous lipid that activates the G protein-couple receptor 18 (GPR18) with vasodilatory activity in resistance arteries. This study investigates its hemodynamic effects and mechanisms of vasorelaxation. Hemodynamic effects of NAGLY in rats were assessed using a Biopac system and its vascular responses were assessed using a wire myograph. NAGLY (1 mg/kg) decreased blood pressure by 69.4±5.5{\%} and reduced renal blood flow by 88±12{\%} and the effects were not sensitive to inhibition by O-1918 (3 mg/kg). In resistant vessels, NAGLY (1–30 µM) induced concentration- and endothelium-dependent vasorelaxation and the effect was inhibited by the nitric oxide synthase inhibitor, L-NAME (300 µM), a cGMP synthase inhibitor, ODQ (10 µM), the antagonists of “endothelial anandamide” receptor, rimonabant (3 µM) and O-1918 (10 µM) and the inhibitor of Na+/Ca2+ exchanger (NCX), KB-R7943 (10 µM). On the other hand, NAGLY-induced vasorelaxation was not affected by CID 16020046 (GPR55 antagonist), AM 251 (cannabinoid CB1 receptor antagonist), AM 630 (cannabinoid CB2 receptor antagonist), capsazepine (TRPV1 antagonist), indomethacin (cyclooxygenase inhibitor), TRAM34 (IKCa channel blocker), iberiotoxin (BKCa channel blocker) and GW9662 (PPARɤ antagonist). At low concentrations of carbachol, NAGLY potentiated carbachol-induced vasorelaxation. NAGLY is an endothelium-dependent vasodilator and hypotensive lipid. The vasorelaxation is predominantly via activation of nitric oxide-cGMP pathway and NCX and probably mediated by the {"}endothelial anandamide” receptor, while the hypotensive effect of NAGLY appears not to involve the anandamide receptor. NAGLY also potentiates carbachol-induced vasorelaxation, the mechanism of which might involve stimulation of NO release.",
keywords = "Hypotensive, N-arachidonoyl glycine, Na/Ca exchanger, Nitric oxide, Vasorelaxation",
author = "{Al Suleimani}, {Yousuf M.} and {Al Mahruqi}, {Ahmed S.}",
year = "2017",
month = "1",
day = "5",
doi = "10.1016/j.ejphar.2016.11.040",
language = "English",
volume = "794",
pages = "209--215",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - The endogenous lipid N-arachidonoyl glycine is hypotensive and nitric oxide-cGMP-dependent vasorelaxant

AU - Al Suleimani, Yousuf M.

AU - Al Mahruqi, Ahmed S.

PY - 2017/1/5

Y1 - 2017/1/5

N2 - N-arachidonoyl glycine (NAGLY), is the endogenous lipid that activates the G protein-couple receptor 18 (GPR18) with vasodilatory activity in resistance arteries. This study investigates its hemodynamic effects and mechanisms of vasorelaxation. Hemodynamic effects of NAGLY in rats were assessed using a Biopac system and its vascular responses were assessed using a wire myograph. NAGLY (1 mg/kg) decreased blood pressure by 69.4±5.5% and reduced renal blood flow by 88±12% and the effects were not sensitive to inhibition by O-1918 (3 mg/kg). In resistant vessels, NAGLY (1–30 µM) induced concentration- and endothelium-dependent vasorelaxation and the effect was inhibited by the nitric oxide synthase inhibitor, L-NAME (300 µM), a cGMP synthase inhibitor, ODQ (10 µM), the antagonists of “endothelial anandamide” receptor, rimonabant (3 µM) and O-1918 (10 µM) and the inhibitor of Na+/Ca2+ exchanger (NCX), KB-R7943 (10 µM). On the other hand, NAGLY-induced vasorelaxation was not affected by CID 16020046 (GPR55 antagonist), AM 251 (cannabinoid CB1 receptor antagonist), AM 630 (cannabinoid CB2 receptor antagonist), capsazepine (TRPV1 antagonist), indomethacin (cyclooxygenase inhibitor), TRAM34 (IKCa channel blocker), iberiotoxin (BKCa channel blocker) and GW9662 (PPARɤ antagonist). At low concentrations of carbachol, NAGLY potentiated carbachol-induced vasorelaxation. NAGLY is an endothelium-dependent vasodilator and hypotensive lipid. The vasorelaxation is predominantly via activation of nitric oxide-cGMP pathway and NCX and probably mediated by the "endothelial anandamide” receptor, while the hypotensive effect of NAGLY appears not to involve the anandamide receptor. NAGLY also potentiates carbachol-induced vasorelaxation, the mechanism of which might involve stimulation of NO release.

AB - N-arachidonoyl glycine (NAGLY), is the endogenous lipid that activates the G protein-couple receptor 18 (GPR18) with vasodilatory activity in resistance arteries. This study investigates its hemodynamic effects and mechanisms of vasorelaxation. Hemodynamic effects of NAGLY in rats were assessed using a Biopac system and its vascular responses were assessed using a wire myograph. NAGLY (1 mg/kg) decreased blood pressure by 69.4±5.5% and reduced renal blood flow by 88±12% and the effects were not sensitive to inhibition by O-1918 (3 mg/kg). In resistant vessels, NAGLY (1–30 µM) induced concentration- and endothelium-dependent vasorelaxation and the effect was inhibited by the nitric oxide synthase inhibitor, L-NAME (300 µM), a cGMP synthase inhibitor, ODQ (10 µM), the antagonists of “endothelial anandamide” receptor, rimonabant (3 µM) and O-1918 (10 µM) and the inhibitor of Na+/Ca2+ exchanger (NCX), KB-R7943 (10 µM). On the other hand, NAGLY-induced vasorelaxation was not affected by CID 16020046 (GPR55 antagonist), AM 251 (cannabinoid CB1 receptor antagonist), AM 630 (cannabinoid CB2 receptor antagonist), capsazepine (TRPV1 antagonist), indomethacin (cyclooxygenase inhibitor), TRAM34 (IKCa channel blocker), iberiotoxin (BKCa channel blocker) and GW9662 (PPARɤ antagonist). At low concentrations of carbachol, NAGLY potentiated carbachol-induced vasorelaxation. NAGLY is an endothelium-dependent vasodilator and hypotensive lipid. The vasorelaxation is predominantly via activation of nitric oxide-cGMP pathway and NCX and probably mediated by the "endothelial anandamide” receptor, while the hypotensive effect of NAGLY appears not to involve the anandamide receptor. NAGLY also potentiates carbachol-induced vasorelaxation, the mechanism of which might involve stimulation of NO release.

KW - Hypotensive

KW - N-arachidonoyl glycine

KW - Na/Ca exchanger

KW - Nitric oxide

KW - Vasorelaxation

UR - http://www.scopus.com/inward/record.url?scp=85000716805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000716805&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2016.11.040

DO - 10.1016/j.ejphar.2016.11.040

M3 - Article

C2 - 27890711

AN - SCOPUS:85000716805

VL - 794

SP - 209

EP - 215

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -